Congratulations to the DCVMN Regulatory Working Group, and to the former Expert Group on Clinical Development & Medical Affairs, which merged into the Regulatory WG in 2025, on the publication of their position paper, “Adaptive clinical trial designs for rapid vaccine development: Developing country vaccine manufacturers’ perspective”, published in the “Vaccine” journal.
The paper highlights how adaptive clinical trial designs can accelerate and optimize vaccine development, and thoughtfully examines the benefits and practical challenges these methodologies pose for regulators, industry and global partners, all seen through the lens of developing-country vaccine manufacturers to accelerate vaccine access beyond pandemic settings.
We extend our heartfelt thanks and congratulations to the Regulatory Working Group members and to the Chair, Mr. Kumar Gaurav, and Co-Chair, Dr. Manish Mahajan MD, who co-authored the paper alongside Dr. Laura B. Martin, PhD, and DCVMN CEO Rajinder Suri, thank you for representing the voice of developing-country vaccine manufacturers so clearly and for all the excellent collaborative work you have done this year.
We are grateful to the Gates Foundation and PATH for their continued support of DCVMN working group activities, which makes achievements like this possible.
We invite colleagues and partners to read the paper and join us in recognizing the Regulatory Working Group’s role in advancing pragmatic, country-centred approaches for faster and safer vaccine access.
📖 Read the full publication here: https://www.sciencedirect.com/science/article/abs/pii/S0264410X25011879?dgcid=coauthor
